Amylin analogs present a strong alternative or complement to GLP-1 receptor agonists, potentially eliciting higher-quality ...

As a GLP-1 receptor agonist, the medication operates through a complex ... as Alzheimer’s and Parkinson’s — due to its ...

Enveda’s pipeline is led by ENV-294, a first-in-class, oral small molecule being developed to treat atopic dermatitis and other inflammatory conditions by combining the advantages of blockbuster drugs ...

After struggling with weight gain for three years, Sarah Bisacca was diagnosed with insulin resistance. Here's how she was learned to manage it.

Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious ...

GLP-1 receptor agonist use is associated with benefits in a number of different disease and may help treat patients with lupus nephritis.

These new challengers are anticipated to account for roughly $70 billion of the total GLP-1 market, which is expected to be worth $200 billion by 2031. Our report on the obesity drug market ...

Before that, it dropped the development of another oral GLP-1 called lotiglipron, after finding a signal that it may cause liver toxicity in some patients. It had been planning to start a phase 3 ...

Novo Nordisk has partnered with Ascendis Pharma on less frequently dosed drugs for obesity and other metabolic diseases, starting with a once-monthly GLP-1 receptor agonist. The Danish pharma ...

“It's all about explaining that different people have different responses,” said Dr. Fatima Cody Stanford, an obesity expert at Massachusetts General Hospital The drugs are known as GLP-1 receptor ...

The company sees this as promising, stating that this patient population “typically lose(s) less weight on GLP-1 therapies.” Moreover, the average hemoglobin A1C (HbA1c) was also lowered by up to 2.2 ...